Market news — every asset we track

Assets

SNGX

Soligenix Shareholders Approve Governance and Capital Changes

Detailed price information for Soligenix Inc (SNGX-Q) from The Globe and Mail including charting and trades.

Sep 22theglobeandmail.com

SNGX: Applying for Vaccine Development Funding for Ebola Vaccine

By David Bautz, PhD NASDAQ: SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Applying for Ebola Vaccine Funding In June 2026, Soligenix, Inc. (NASDAQ: SNGX) announced that it would be applying for funding from a recent call for proposals from the Coalition for Epidemic Preparedness Innovations (CEPI) regarding vaccine development for Bundibugyo virus. Soligenix will be applying in

Aug 12Yahoo Finance

SNGX

Soligenix culls topical lymphoma asset after Phase III miss

The company will now focus on developing its rare disease pipeline candidate and ambient-stable vaccine platform.

Aug 10Yahoo Finance

SNGX

Soligenix (SNGX) Receives a Buy from Alliance Global Partners

Detailed price information for Soligenix Inc (SNGX-Q) from The Globe and Mail including charting and trades.

Aug 8The Globe and Mail

SNGX

Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results

PRINCETON, N.J. , Aug. 7, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical...

Aug 7Barchart.com

SNGX

This is the newest page. Registered accounts read further back.